Gammacan Appoints World Renowned Immunohematologist, Dr. Jacob Nusbacher as Medical Advisor to Oversee Phase II GCAN 101 Clinica
November 02 2005 - 7:30AM
Business Wire
Activity Initiated by Company and Dr. Nusbacher Filing Provisional
Patent for Treatment of Avian Flu Utilizing IVIg Therapy Gammacan
International (OTC BB:GCAN), a developer of immunotherapies for
cancer and other diseases, today announced that Dr. Jacob Nusbacher
has accepted an appointment as Medical Advisor to the Company to
oversee the Phase II Clinical trial of GCAN 101 for the treatment
of metastatic cancer and to expand the Company's pipeline in
plasma-based products. The Company concurrently announced that in
line with Dr. Nusbacher's mission of expanding Gammacan's platform
of IVIg-based products it filed a Provisional Patent with the U.S.
patent office for the utilization of IVIg therapy as a potential
treatment for avian flu using IVIg from previously infected
patients and from those previously immunized. IVIg has been
efficacious in treating other viral diseases such as Hepatitis B,
and Rabies. "Dr. Nusbacher's research and experience in hematology,
immunology, and plasma coupled with his expertise in initiating and
managing clinical trials is truly extraordinary and will be of
great assistance to Gammacan as we continue our Phase II trial of
GCAN 101 for the treatment of metastatic cancer," stated Vered
Caplan, CEO. A major east coast publication, reported yesterday in
an article focused on avian flu, "We know that viruses mutate and
strike in unpredictable ways. It is plausible that this virus might
mutate as has been predicted and that an epidemic - or even a
pandemic - might result. Since we cannot predict exactly how,
where, or when the virus might mutate, we need a response that is
both preventative and adaptive." Vered Caplan, CEO, commented, "We
believe that Dr. Nusbacher's expertise will be of great assistance
in furthering the Company's product pipeline. Because of the
serious public health hazard that avian flu could present, Gammacan
is presently exploring the possibilities that IVIg may hold in this
area." About Dr. Nusbacher Dr. Nusbacher is a leading expert in the
field of immunohematology, and has extensive experience in both the
scientific and business aspects of human plasma- derived therapies.
Prior to joining GammaCan, he served as Medical Director of Kamada
Ltd, a pharmaceutical company specializing in drugs manufactured
from human plasma. He has also served as National Director of the
Canadian Red Cross Blood Transfusion Service and has directed major
regional blood centers in the United States and Canada. In
addition, Dr. Nusbacher has held the position of Professor of
Medicine at the Universities of Rochester, Pittsburgh and Toronto,
and was Visiting Professor at Tel Aviv University. He has more than
100 scientific publications to his credit. Dr. Nusbacher has also
served as a member of the first FDA Panel on Blood and Blood
Products (BPAC) for five years and on the Editorial Board of the
Journal Transfusion for 20 years. Dr. Nusbacher has and has
designed and led clinical trials for a number of different drugs as
part of the process in obtaining FDA approval. He has consulted for
major U.S. companies including DuPont, Bayer, and Alpha
Therapeutics. About GammaCan: GammaCan is focusing on the
commercialization of a revolutionary anti-cancer immunotherapy that
the Company believes will be proven to be effective in reducing the
metastatic spread of a wide range of cancers. GammaCan's proposed
treatment is based on IVIG, a safe, relatively non-toxic human
plasma-based product, currently used to treat a variety of immune
deficiencies and autoimmune diseases. It works by strengthening the
patient's immune system. Many experts currently view immunotherapy
as a future alternative to today's standard chemotherapy.
Approximately twenty companies produce IVIG, and annual worldwide
sales are currently in excess of 50 metric tones with an estimated
value in excess of 1.5 billion USD. IVIG is commonly used to treat
certain autoimmune diseases and blood disorders and to replace the
antibodies in people who are unable to produce them. For more
information about GammaCan visit www.gammacan.com or call the
company's headquarters in Givat Shmuel, Israel at 972 3 5774475.
Safe Harbor Statement: Statements in this document that are not
purely historical are forward-looking statements. Forward-looking
statements in this release include statements regarding: the
commercialization of an anti-cancer immunotherapy and the Company
developing the boosting of cancer patients' immune systems with
IVIG into an effective treatment. Actual outcomes and the Company's
actual results could differ materially from those in such
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as the
inability to finance the planned development of the technology,
inability to hire appropriate staff to develop the technology,
unforeseen technical difficulties in developing the technology,
inability to obtain regulatory approval for human use, competitors'
therapies proving more effective, cheaper or otherwise preferable
for consumers, inability to market the product we produce, among
other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further
risk factors see the risk factors associated with other early stage
medical research and development companies filed with the SEC on
Edgar.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024